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Natural, polyreactive, low-affinity antibodies are known to play an important role not only 
in the immediate defense against pathogens, but also in shaping the acquired immune response. 
On the other hand, antigen specific, high-affinity antibodies can affect the balance of natural 
antibodies and lead to autoimmune diseases. In this study we have analyzed the changes that occur 
in the IgM and IgG pool of natural antibodies after immunization with split or whole virion 
influenza vaccine. For this purpose, “in-house” developed ELISAs were used. The subjects were 
divided, according to the vaccination status, into those who had been immunized with the 
influenza vaccine in previous years and those who had been immunized for the first time. The 
analysis indicated that the pool of natural antibodies was not impaired by the immunization, 
evidenced by the lack of changes in any of the groups, and that certain fluctuations were induced 
in order to maintain the homeostasis of the immune system. 
 











It is well known that acquired immunity and the existence of high-affinity 
antibodies plays a fundamental role in the successful defense of the organism from 
pathogens. But before the encounter with acquired immunity, the intruders first meet the 
innate immune system of which natural antibodies (NAbs) are an important component 
(1). The presence of “natural autoantibodies” in healthy individuals was demonstrated by 
Besredka approximately 100 years ago (2). Since then, the role of these antibodies in the 
body's defense against pathogens, the method of isolation (cold alcohol fractionation from 
pooled plasma from 3000-10,000 healthy blood donors, additional precipitation 
procedures to remove the non-immunoglobulin G proteins and ion exchange 
chromatography to further separate out IgGs (3)) and the use as therapy have been 
established (4). However, many issues remain unclear, including the interaction / 
dependence of natural and induced antibodies, which may be important for planning new 
vaccines and immunization methods. 
NAbs are immunoglobulins, mainly of the IgM, IgG and IgA (5) classes and 
function as part of the innate immune system present in healthy individuals, including 
virtually all vertebrate species. These antibodies are germline determined, polyreactive, 
usually with low affinity and can recognize both endogenous and foreign antigens. An 
individual's natural antibody pool is formed early in the ontogeny and stays constant 
within a 20-year interval (6,7), while induced antibodies become heterogeneous over time 
(8). 
Natural IgM (NIgM) is the earliest antibody isotype to be expressed during immune 
system development and is well represented in the circulation after birth, before the 
exposure to foreign antigens (9). Natural IgG repertoire (NIgG) is established within the 
first 2-4 years of life and it is highly homogenous among children and similar to the one 
expressed by healthy adults. Most of the NAbs in adult serum are of the IgG class (5,9).  
The most important role of NAbs is to provide key protection during the period 
between the onset of infection and the emergence of the adaptive immune response. Thus, 
these antibodies provide the initial defense against invading pathogens. Moreover, 
acquired immunity is not sufficient to protect an animal from the disease, such as 
influenza virus infection in the absence of NAbs in the body (10). 
NAbs play a role in maintaining the homeostasis of the immune system, as well as 
regulating the immune response itself, through an idiotypic network whose significance 
was demonstrated in 1974 by Jerne (11).  Idiotypes are the antigenic determinants in the 
variable region of antibodies which are recognized by anti-idiotypic antibodies. 
The idiotypic network comprises the interaction of both idiotypic and anti-idiotypic-
bearing antigen receptors on lymphocytes and idiotypic and anti-idiotypic antibodies. In 
case of an action of a sufficiently strong factor that disrupts the idiotypic network, the 




pathological state of the organism in terms of the occurrence of autoimmune diseases, 
which is shown in mice (12,13,14,15). The understanding of the relationship between 
vaccination and NAbs is further underlined by the fact that hyperimmunization can also 
act as a powerful autoreactivity-inducing factor (16,17). 
Another important role of NAbs has been identified in which immune complexes 
of antigens with natural antibodies activate complement and regulate T-cell mediated 
immunity, playing a role as endogenous adjuvant (18). 
On the other hand, the secretion of NAbs of different isotypes is differently 
regulated and differently sensitive to the action of various factors. In a mouse model, self-
antigen stimulation was shown to be sufficient to maintain NIgM levels, while foreign 
antigen stimulation (Streptococus pneumonie, influenza virus) was required to maintain 
NIgG and NIgA levels (19). It has also been shown that the change in NIgG depends on 
the diet, environmental factors and aging, but not on NIgM secretion (20). All this 
indicates that the cells that secrete different isotypes of NAbs react differently to external 
stimuli. 
Given their polyreactive nature, NAbs have the ability to recognize various 
influenza virus epitopes. In a mouse model, it was shown that after NAbs binding to the 
influenza virus (21,22), components of the complement system bind to formed 
immunocomplexes, thus neutralizing the virus (23), but not inducing virolysis. In 
addition, NIgM promotes pathogen recognition by antigen presenting cells (APCs) and 
influence the polarization of the immune response (Th1/Th2) (24). Moreover, NIgM is 
partially protective in antibody-deficient mice during the early phases of infection (23). 
Another important role of NIgM is to contribute to the formation of the acquired memory 
response. Specifically, it has been shown that for long-term memory response to influenza 
virus, mice require both complement and NAbs (25), suggesting that it would be 
especially important to examine this relationship during the immunization against 
influenza in humans.  
Due to particularly high genetic variability of influenza virus, vaccination is advised 
annually to reduce the burden of the influenza disease. On the one hand, successful 
protection against influenza virus requires both types of host immunity, innate and 
acquired (26), and on the other hand, previous immunization with a seasonal vaccine 
affects the acquired immune response after subsequent vaccination the following season, 
through the phenomenon of crossreactivity between similar epitopes. For example, the 
analysis of human sera and ferrets’ sera suggest that the specificity of pandemic H1N1 
antibody responses can be shifted to epitopes near the HA receptor–binding domain after 
sequential infections with seasonal H1N1 and pandemic H1N1 viruses that share 
homology in this region (27). Considering all the aforementioned, we examined the effect 
of immunization with influenza vaccine on innate humoral immunity (NAbs pool) in 
humans. This effect is particularly important given that influenza vaccination is repeated 
once a year, which could possibly lead to a decrease in the overall antiviral response, in 
part because of the disruption of the healthy immune compartment by changing the 




For this reason, we examine whether immunization induces changes in the NAbs 
composition in humans, as well as the trend of these changes. Addressing this issue may 
also be important because of the need to immunize humans against the SARS-CoV-2 
virus and the impact that natural antibodies may have on it, especially since annual 
revaccination is one of the options being considered. 
For NIgM analysis, we used a mouse monoclonal antibody (MoAb) Y7, specific to 
the idiotope located in the antigen binding site of human natural IgM (29). We have 
previously documented that human IgM molecules expressing Y7 idiotope exert NAb 
properties, i.e. binding to ssDNA, phospholypids, peptidoglycan and bacterial cells 
(30,31). 
Using MoAb Y7, we analyzed the effect of immunization against influenza on the 
pool of total and influenza-specific NIgM antibodies. The effect of immunization on the 
pool of total NIgG antibodies was assessed based on the binding of IgG antibodies to 
autoantigens (phosphatidyl serine (PtS), mouse laminin, ganglioside GM1, dsDNA). At 
the same time, we compared whether the vaccination status of patients (first-time 
immunized patients vs. patients immunized during previous seasons), as well as the type 
of vaccine administered (whole virus or split) could affect the expression of NAbs. 
Materials and methods 
Study design and participants 
Collection of human sera samples for monitoring the immune response after 
immunization with trivalent influenza vaccines for 2003/2004 season was conducted 
between September and December 2003 in Serbia, in accordance with the Declaration of 
Helsinki and the International Conference on Harmonization-Good Clinical Practice. The 
study protocol was approved by an Institutional Review Board of the Institute of 
Virology, Vaccines and Sera "Torlak" (Belgrade, Serbia). Written informed consent was 
obtained from all participants. Healthy individuals (health care workers) 18–45 years old 
were enrolled. For those reporting previous influenza vaccination, documentation 
(Vaccination Card/record) was provided. None of the participants were sick or had a 
diagnosis of autoimmune disease; none of them participated in different studies and no 
woman was pregnant. The total duration of the study was one month. Serum samples 
from n = 35 participants were collected before (pre-vacc) and 30 days after (post-vacc) 
seasonal influenza vaccination. Paired serum samples were investigated at the Institute of 
Virology, Vaccines and Sera "Torlak" (Belgrade, Serbia).  
Trivalent influenza vaccines for season 2003/2004, both whole virion and split, for 
the northern hemisphere contained the following strains as recommended by the World 
Health Organization (WHO) and the Committee for Medicinal Products for Human Use 
(CHMP) of the European Medicines Agency (EMA): A/New Caledonia/20/99(H1N1)-
like virus, A/Moscow/10/99(H3N2)-like virus and B/Hong Kong/330/2001-like virus. 
The first group of 14 participants was immunized with the whole virion influenza vaccine 




years and 9 were vaccinated for the first time. Another group of 21 participants was 
immunized with the split vaccine, manufactured by Sanofi Pasteur, France, of which              
8 patients had been immunized during previous years and 13 were vaccinated for the first 
time. Each participant was immunized i.m. with 45 g/dose HA (15 mg HA of each virus 
strain). Blood samples were collected by venipuncture prior to and four weeks after 
immunization. Collected sera were complement depleted (30 min on 56 ºC), aliquoted 
and stored at –20 ºC until used for analysis. The sera were analyzed shortly after the 
collection of all samples. 
ELISA for detection influenza A H1N1 New Caledonia/20/99(H1N1) – specific 
IgG 
The intensity of the immune response after immunization of patients with influenza 
vaccine was evaluated by measuring influenza A H1N1 HA – specific IgG.  
Whole virion A H1N1 New Caledonia/20/99 (antigen that was part of the vaccine 
composition for season 2003-2004) was adsorbed onto microtiter plates (Nunc MaxiSorp) 
at a concentration of 2.5 g/ml HA in phosphate buffered saline (PBS), 50 l/well, by 
overnight incubation at 4 ºC. The plates were then washed four times with PBS                         
(200 l/well), saturated with 1% bovine serum albumin (BSA)/PBS (200 l/well) and 
incubated for 2 h at room temperature. The sera were diluted 1:500 in 0.05% Tween 
20/1% BSA/PBS and 50 l were added to each well in duplicate. After incubation for 2 
h at room temperature and a new cycle of washing, biotinilated anti-human IgG antibodies 
(Sigma-Aldrich, B3773) were added to wells according to manufacturer instructions. The 
color was developed by streptavidin peroxidase/OPD system. The reaction was stopped 
by adding 50 l 2M H2SO4 and absorbance was monitored at 492 and 692. 
Sandwich ELISA for detection of total natural IgM in patient sera 
Total NAbs were determined using the mouse MoAb Y7, specific for natural 
idiotope expressed on human antibodies. MoAb Y7 was produced in our laboratory by 
hybridoma technology, after the immunization of mice with a natural human IgM 
antibody (32). The specificity of this antibody was characterized in detail, and method for 
measuring the levels of antibodies carrying this natural idiotope previously established 
(33). 
Briefly, a 96-well microtiter plate (MaxiSorp plates, Nunc) was coated with 
commercial goat anti-human IgM (Sigma-Aldrich, B1265), 50 l/well, at 4 ºC, overnight. 
After saturation with 1% BSA/PBS, (200 l/well, 1 h, RT) and washing, three times with 
0.05% Tween 20/PBS (Sigma - Aldrich Co., St. Louis, Mo.) and once with PBS                       
(200 l per well), the wells were incubated with human sera at 1:500 dilution in                           
1% BSA/PBS, at room temperature for 1 h. After the next washing cycle, MoAb Y7 was 
added at a final concentration of 2.5 g/ml. The presence of the natural idiotope on 
captured sera IgM was detected by peroxidase-conjugated goat anti-mouse IgG (Sigma, 




Competitive ELISA for detection of influenza A H1N1 New Caledonia 20/99 
HA -specific natural IgM 
Since MoAb Y7 binds to idiotopes located in the antigen binding site on 
immunoglobulins, natural antibodies specific for influenza antigens were indirectly 
detected, using inhibitory ELISA. Two sets of plates were prepared for the purpose of 
inhibitory ELISA – one with and the other one without the inhibitor (MoAb Y7). The 
plates were prepared as described for the ELISA for detection of influenza A H1N1 – 
specific IgG. After saturation, MoAb Y7, concentration of 200 ng/ml, was mixed with 
human sera previously diluted in 1% w/v BSA/PBS (final dilution of 1:3000) and pre-
incubated for 2 hours at 37 °C. Concentration of 200 ng/ml was determined by ELISA, 
according to the binding curve of MoAb Y7 to the polyspecific natural human antibody 
IgMDJ which expresses Y7 idiotope (33). The mixture was next added to the first set of 
plates. Simultaneously, the same human sera in the same dilution but without MoAb Y7 
were added to the second set of plates. Both sets of plates were then incubated for one 
hour at room temperature. For the detection of HA-specific IgM antibodies, biotinylated 
anti-human IgM antibody was used, prepared according to the manufacturer's 
instructions. ExtrAvidin® peroxidase/OPD was used as a detection system (Sigma-
Aldrich). The difference in absorbance values obtained between the sera incubated with 
MoAb Y7 and those that were incubated without MoAb Y7 correlated to the relative 
levels of natural HA-specific IgM antibodies. Specifically, lower percent of inhibition 
indicated lower percent of HA-specific NIgM. 
ELISAs for detection of natural (autoantigen specific) IgG in patient sera  
In order to measure the level of different auto-antibodies in the sera of immunized 
people, we used the following autoantigens: phosphatidylserine (PtS), gangliosideGM1, 
dsDNA and mouse laminin (all purchased from Sigma). PtS was dissolved in absolute 
ethanol at a concentration of 10 g/ml, adsorbed onto microtiter plate (PolySorp, Nunc) 
and kept at room temperature until ethanol evaporated. The plates were then blocked with 
1% BSA/PBS and the sera (diluted 1:400 in 1% BSA/PBS) were added (50l/well). The 
subsequent steps were performed using biotinylated anti-human IgG antibodies and the 
signal was developed as described previously.  
Anti-dsDNA ELISA was performed by adsorbing poly-L-lysine (250 ng/ml in PBS) 
(Sigma) to each well of the MaxiSorp plate (Nunc) for 30 min at RT. The plate was then 
flicked and dsDNA (10 g/ml) was added to the wells. For the purpose of detecting anti-
dsDNA antibodies, we used dsDNA from calf thymus (Sigma-Aldrich, D1501). After 
that, the plate was incubated over night at 4 °C. The plate was then fixed with 0.5% 
glutaraldehide/PBS for 15 min, washed with PBS and blocked with 1% BSA/PBS. The 
sera for anti-dsDNA ELISA were diluted 1:400 in 1% BSA/PBS and 50 l was added to 
wells. All subsequent steps were performed as described previously. 
For the purpose of anti-laminin ELISA, laminin (10 g/ml in PBS) was adsorbed 
onto PolySorp microtiter plate (Nunc) and incubated overnight at 4 °C. After blocking 




added at the dilution of 1:200. All subsequent steps were performed as described 
previously. 
Statistical Analysis 
The statistical analysis of the obtained data was performed using OriginPro 
Software and paired t-test. Absorbance values obtained for sera from participants prior to 
immunization were used as reference values. A P-value of 0.05 was considered as the 
limit of statistical significance. 
Results 
Specific immune response to influenza vaccine 
The study was organized as an internal pilot study, in order to compare the newly 
developed whole virus vaccine produced at the Institute Torlak with a commercial 
vaccine, and regarding the actual pandemic situation we felt the obtained results were 
important both for health professionals and the general public.  
In order to adequately analyze the effects of immunization on the pool of NAbs, we 
had to make sure that the influenza vaccine successfully triggered the specific immune 
response. Therefore, we evaluated the level of influenza A H1N1 New Caledonia specific 
IgG before and four weeks after immunization. We detected an increase in anti-H1N1 
specific IgG, regardless of whether immunization was performed with a whole virus or 
split vaccine (Figure1). In addition, the immune response was triggered in both previously 
immunized patients and in patients for whom this was the first influenza vaccination 
(Figure 1). The relative change in the immune response was higher in patients who were 
not previously vaccinated, regardless of which type of vaccine was used. 
Total natural IgM after immunization 
Since NIgM is not as short-lived as the IgM that occurs at the beginning of 
immunization, we were able to analyze it in sera taken four weeks after immunization 
(Figure 2). By comparing the levels of NAbs in human sera before and after immunization 
with influenza vaccine, it was found that immunization did not lead to a change in NIgM 
antibody levels.  
Influenza- specific natural IgM 
The A H1N1 New Caledonia/20/99-specific NIgM antibodies were detected 
indirectly, by analyzing the degree of inhibition using natural idiotope-specific MoAb 
Y7- the greater the degree of inhibition of binding to A H1N1 antigen, the greater the 
amount of A H1N1-specific natural IgM antibodies in the patients’ sera (Figure 3). Given 
that the analysis was performed four weeks post immunization, the potential contribution 
of the “adaptive” virus-specific IgM to the overall immune response was negligible, since 
the “adaptive” IgM is typically not detected so late post-immunization. Based on the 
detected inhibition of NIgM antibodies specific to the virion HA, it could be concluded 




vaccinated for the first time, the decrease was not statistically significant, while in 
subjects who had been immunized in previous years, a statistically significant decrease 
was detected. 
Figure 1.  Changes in level of serum IgG antibodies against A H1N1 influenza virus strain 
after immunization with (A) whole virion vaccine, in patients who were not 
previously vaccinated; (B) whole virion vaccine, in patients who were vaccinated 
in previous years; (C) split vaccine, in patients who were not previously vaccinated; 
(D) split vaccine, in patients who were vaccinated in previous years. Open columns 
represent IgG levels before immunization; columns with wide stripes represent 
IgG levels after immunization. Data are presented as means ± SEM. *p<0.5, 
**p<0.05. 
 
Slika 1.  Promena nivoa serumskih IgG antitela specifičnih za A H1N1 soj influence virusa 
kod pacijenata nakon imunizacije sa (A) celovirusnom vakcinom, ranije nisu 
vakcinisani; (B) celovirusnom vakcinom, ranije vakcinisani; (C) split vakcinom, 
ranije nisu vakcinisani; (D) split vakcinom, ranije vakcinisani. Beli stubići 
označavaju IgG nivo pre, a šrafirani nakon imunizacije. Podaci su prikazani kao 
srednja vrednost ± SEM.  *p<0.5, **p<0.05. 
Figure 2.  Changes in total serum NIgM antibody levels after immunization with (A) whole 
virion vaccine, in patients who were not previously vaccinated; (B) whole virion 
vaccine, in patients who were vaccinated in previous years; (C) split vaccine, in 
patients who were not previously vaccinated; (D) split vaccine, in patients who 
were vaccinated in previous years. Open columns represent NIgM levels before 
immunization; columns with wide stripes represent NIgM levels after 
immunization. Data are presented as means  ± SEM. 
 
Slika 2.  Promene u nivou ukupnih serumskih NIgM antitela pacijenata nakon imunizacije 
sa (A) celovirusnom vakcinom, ranije nisu vakcinisani; (B) celovirusnom 
vakcinom, ranije vakcinisani; (C) split vakcinom, ranije nisu vakcinisani; (D) split 
vakcinom, ranije vakcinisani. Beli stubići označavaju NIgM nivo pre, a šrafirani 




Figure 3:  The percentage of inhibition of natural influenza A H1N1-specific IgM  
 antibodies with natural idiotope-specific MoAb Y7 upon immunization with  
 (A) whole virion vaccine, in patients who were not previously vaccinated;  
 (B) whole virion vaccine, in patients who were vaccinated in previous years;  
 (C) split vaccine, in patients who were not previously vaccinated; (D) split  
 vaccine, in patients who were vaccinated in previous years. Open columns  
 represent the percentage of inhibition before immunization; columns with  
 wide stripes represent the percentage of inhibition after immunization. Data  
 are presented as means ± SEM. **p<0.05 
 
Slika 3:  Procenat inhibicije prirodnih influenza A H1N1-specifičnih IgM antitela  
 pomoću Y7 monoklonskog antitela specifičnog za prirodni idiotop nakon  
 imunizacije sa (A) celovirusnom vakcinom, pacijenti koji ranije nisu  
 vakcinisani; (B) celovirusnom vakcinom, ranije vakcinisani pacijenti; (C)  
 split vakcinom, pacijenti koji ranije nisu vakcinisani; (D) split vakcinom,  
 ranije vakcinisani pacijenti. Beli stubići označavaju procenat inhibicije pre,  
 a šrafirani nakon imunizacije. Podaci su prikazani kao srednja vrednost                    
 ± SEM.  **p<0.05 
 
 
Natural IgG after immunization 
We defined NIgG antibodies as antibodies to following self-antigens: 
phospholipids, gangliosides, mouse laminin, and dsDNA (Figure 4). The analysis of the 
presence of immunoglobulins of these specificities in the sera of subjects before and after 
immunization with influenza vaccine did not reveal a significant change in the levels of 
NIgG antibodies induced by the vaccination. The result was not dependent on the 
vaccination status of the subjects, the type of the vaccine received, or the nature of the 





Figure 4:  Changes in serum NIgG antibody levels specific to self-antigens, after immunization 
(A) with whole virion vaccine, in patients who were not  previously vaccinated;  
 (B) with whole virion vaccine, in patients who were vaccinated in previous years; (C) 
with split vaccine, in patients who were not previously vaccinated; (D) with split 
vaccine, in patients who were vaccinated in previous years. Open columns represent 
IgG levels before immunization; columns with wide stripes represent IgG levels after 
immunization. Row I: Anti- dsDNA IgG; row II: Anti- GM1 IgG; row III:  
 Anti-laminin IgG; row IV: Anti- PtS IgG. Data are presented as means ± SEM. 
 
Slika 4:  Promene u nivou serumskih NIgG antitela specifičnih za sopstvene antigene nakon 
imunizacije pacijenata sa (A) celovirusnom vakcinom, ranije nisu vakcinisani;  
 (B) celovirusnom vakcinom, ranije vakcinisani; (C) split vakcinom, ranije nisu 
vakcinisani; (D) split vakcinom, ranije vakcinisani. Beli stubići označavaju NIgG 
nivo pre, a šrafirani nakon imunizacije. Red I: Anti- dsDNA IgG; red II: Anti- GM1 
IgG; red III: Anti-laminin IgG; red IV: Anti- PtS IgG. Podaci su prikazani kao 





By analyzing the levels of IgG specific for influenza A H1N1 New Caledonia virus, 
we confirmed that both influenza vaccines, whole virion and split, successfully triggered 
an immune response, which was a prerequisite to further conduct the analysis of NAbs 
during immunization. In addition, judging by the serum level of H1N1-specific 
antibodies, immunogenicity of the split and whole virion vaccines was similar. No matter 
what type of vaccine was used, the immune response, judging by the increase in serum 
level of H1N1-specific antibodies after vaccination, was more successful in people who 
had never been immunized against the flu (compared differences in anti-H1N1 IgG levels 
between corresponding pre- and post-vaccination samples) because what was measured 
was a relative change in antibody levels, which is more obvious in this group. The weaker 
immune response observed in people previously immunized with the seasonal influenza 
vaccine is already known in the literature as the Hoskins effect (antigenic sin) (34,35). 
The Hoskins effect refers to the phenomenon that the immune system preferentially uses 
the immune memory acquired by a previous infection (or immunization) when 
encountering a new antigen that is very similar to the previous one. The immune system 
"trapped" by the first response is unable to achieve a potentially more efficient response 
during subsequent infections (immunizations), which can cause an inadequate immune 
response to a new strain of the virus. One must keep in mind that this phenomenon is 
related to both vaccination and infection, as the annual influenza burden was about 14% 
worldwide (36). Therefore, it is common practice to use laboratory animals to study innate 
immunity against influenza viruses. However, there are specific characteristics of the 
human immune response that cannot be analyzed using laboratory animals (37). 
MoAb Y7 specific for human natural antibodies allowed us to distinguish natural 
from “adaptive” IgM antibodies and analyze the effect of immunization with different 
types of influenza vaccine on the total NIgM pool, as well as on NIgM specific for 
influenza antigens. 
We found that immunization with the influenza vaccine did not induce a change in 
total NIgM antibodies, regardless of which type of vaccine was used (whole virion or 
split), as well as whether the subject had been previously immunized against influenza. 
This result was expected and desirable, given that a significant change in the amount of 
NAbs could lead to the imbalance of the idiotypic network and cause negative effects. 
Preservation of the total pool of NIgM is especially important because it has been shown 
that a decrease in these antibodies leads to enhanced production of pathogenic IgG 
autoantibodies and autoimmune disease (38). The primary role of NAbs is to maintain 
homeostasis of the immune system (39,40). At the same time, it enables a delicate balance 
between the organism and commensal bacteria on one hand, and a strong immune 
response to pathogens, on the other hand. A strong stimulus, such as repeated 
immunizations or hyperimmunizations, can upset this balance, and thus lead to a 
pathological state. The obtained results showed that the functionality of the idiotypic 




Our analysis detected a decrease in influenza-specific NIgM antibodies, especially 
in subjects who had been previously immunized with the influenza vaccine. At the same 
time, no change in total NIgM was observed after immunization, regardless of the type 
of vaccine used, and regardless of the vaccination status of the subjects. It is possible that 
the proportion of HA-specific NIgM antibodies in the total NIgM pool was so small that 
their change could not affect the total NIgM pool. 
A change in antigen-specific NIgM can be considered an "imprint" left by 
immunization. Namely, in the groups of subjects who were immunized for the first time, 
the levels of these antibodies decreased, although without statistical significance. In the 
groups of subjects previously immunized with the influenza vaccine, subsequent 
immunizations led to a more pronounced decrease in the levels of these antibodies, i.e. 
the observed change became statistically significant. The reason for the decrease in HA-
specific NIgM may be that these antibodies performed their "duty" to remove foreign 
antigens, in this case influenza virus antigens, with the period after immunization being 
too long for the levels to recover. Another possible explanation for the decrease in 
antigen-specific NIgM is that this pool was used to produce vaccine-induced highly 
specific antibodies. Similar conclusions were reached by the authors who noticed this 
phenomenon in animal models (41,42). It has been shown that immunization of laboratory 
animals can induce an increase in the pool of NAbs, which are not pathological 
(autoimmune), but contribute to strengthening of the homeostasis of the immune system. 
As most of the NAbs in adult serum are of the IgG class, we examined the change 
in NIgG after immunization. For this purpose, we analyzed natural autoantigen-specific 
IgG binding to phospholipids, gangliosides, laminin, and dsDNA. These antibodies differ 
from pathological antibodies of the same specificity in affinity and the amount in the 
patients’ serum. Significant levels of anti-dsDNA antibodies are considered to be 
confirmatory in the diagnosis of SLE (43) and their serum concentration correlates with 
the severity of the disease. An increase in antibodies specific for phospholipids, including 
PtS, is one of the characteristics of antiphospholipid syndrome (APS) (34). Antibodies to 
ganglioside GM1 (anti-GM1 antibodies) have been implicated in the pathogenesis of 
Guillain–Barré syndrome (GBS) (45), multifocal motor neuropathy (MMN) (46) and 
motor neuron disease (47). Anti-laminin IgG occurs in autoimmune-mediated 
reproductive failures, a skin pathology due to dermal-epidermal junction disorders 
(Mucous membrane pemphigoid). Mouse laminin used in this study is known to contain 
a carbohydrate epitope, known as the -Gal epitope, and antibodies recognising this 
epitope are represented by 1% of total natural antibodies (48). Influenza virus vaccines 
expressing -Gal epitopes are opsonized by anti-Gal immunoglobulin G, inducing 
effective uptake of the vaccine virus by APC and thereby stimulating influenza virus-
specific T cells and eliciting a protective immune response (49), so possible fluctuations 
in its representation may be influential. Our results indicate no change in this respect. 
As autoimmune diseases are probably caused and triggered by multiple 
environmental factors, one could theoretically speculate that the flu vaccine, as an 




dsDNA, anti-PtS IgG, anti-GM1 IgG and anti-laminin IgG antibodies are also part of the 
repertoire of natural IgG. Our results indicate that there was no change in the level of 
NIgG specific for the listed autoantigens, nor the appearance of pathological antibodies.  
It is especially important to note that even repeated immunization with influenza vaccine 
did not indicate changes in the direction of autoimmunity. 
In literature (24), there are assumptions that autoimmune diseases could be caused 
by a disorder of the idiotypic regulatory network in which NAbs play a significant role. 
Our results did not indicate that there were changes in the pool of NAbs of either IgM or 
IgG isotypes that would lead to a pathological outcome. In other words, it was shown that 
the pool of NAbs remains stable during immunization with influenza vaccine. The type 
of antigen and the vaccine status of the patient did not affect the stability of the pool. The 
observed fluctuations of HA-specific NIgM are most likely necessary to establish a new 
equilibrium in the NAb pool after the entry of a foreign external factor, in this case the 
vaccine antigen. 
In animal models, the relationship between natural and acquired antibodies can be 
described as follows (41). The levels of NAbs and induced Abs negatively correlate: in 
individuals with high levels of NAbs, antigen-specific antibodies develop less and vice 
versa. Because vaccination leads to the consumption of NAbs and in the first stage of 
developing a specific immune response, it may appear that there is a false tolerance to the 
vaccine antigen or a false suppression of the immune response. This means that the use 
of suboptimal doses and/or an inappropriate antigen formulation for vaccination can 
result in a significant reduction in the levels of protective (specific) NAbs without 
establishing an appropriate response. 
The studies of the maintenance of NAb homeostasis and the fluctuations that occur 
during immunization, as well as the impact of the vaccine antigen used on this 
homeostasis are clearly very important, especially in certain vulnerable human 
populations. In the current situation of the SARS-CoV-2 virus pandemic, it would be 
particularly useful to analyze immune homeostasis after immunization of humans with 
the SARS-CoV-2 antigens, to determine whether these antigens have an effect on NAbs 
homeostasis, and whether repeated vaccinations each year may shift the pool of NAbs to 
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Prirodna, polireaktivna i slabo afinitetna antitela igraju važnu ulogu ne samo u neposrednoj 
odbrani od patogena, već i u oblikovanju stečenog imunskog odgovora. S druge strane, indukcija 
visoko afinitetnih, antigen - specifičnih antitela, može uticati na ravnotežu prirodnih antitela i 
time dovesti do autoimunskih bolesti. U ovoj studiji analizirali smo da li imunizacija ljudi split ili 
celovirusnom vakcinom protiv gripa može dovesti do promena u IgM i IgG pulu prirodnih 
antitela. Za analizu su korišćeni “in-house” razvijeni ELISA testovi. Ispitanici su podeljeni prema 
vakcinalnom statusu na one koji su prethodnih godina bili imunizovani vakcinom protiv gripa i 
one koji su prvi put imunizovani. Pokazano je da imunizacijom nije narušen ukupan pul prirodnih 
antitela ni u jednoj grupi i da je došlo do određenih fluktuacija u nivoima prirodnih antitela kako 
bi se održala homeostaza imunskog sistema. 
 
Ključne reči: prirodna antitela, imunizacija, imunološka homeostaza 
 
 
 
 
 
 
 
